AI주식인사이트AI Stock Insight
C

테라젠이텍스

066700KOSDAQ의약품 제조업

53.5 / 100

Reference Date: 2026-06-10

Financial Score28.0 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE significantly exceeds the industry average but Operating Profit is on a declining trend. Plunged 17.7% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Teragen I-teks operates primarily in pharmaceutical manufacturing and sales, as well as genomic sequencing services. Its subsidiaries, Lead Pharm and Teragen Healthcare, specialize in specialty drug distribution and non-drug medical product sales, respectively. Additionally, Teragen Bio and overseas subsidiaries are expanding genomic analysis services into the Chinese market.

Number of Employees

222people

Average Salary

50.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
8.01Industry Average 11.936.5Point

Lower than industry avg (good)

PBR
0.55Industry Average 0.895.5Point

Lower than industry avg (good)

ROE
8.11Industry Average 4.017.0Point

2.0x industry avg (excellent)

Debt Ratio
5.84Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲10.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼5.1% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -0.4% (declining, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,370Won52-week high 3,31552-week low 2,370
1-month return0.0Point

1m -17.71% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral분기보고서 (2026.03)2026-05-15